|
Market Closed -
Other stock markets
|
After hours 00:59:01 | |||
| 924.37 USD | -1.39% |
|
927.45 | +0.33% |
| 11-07 | UBS Adjusts Price Target on Eli Lilly to $1,080 From $895, Maintains Buy Rating | MT |
| 11-07 | Novo Nordisk, Lilly shares slip on US drug pricing deal | RE |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- LLY Stock
- Consensus Eli Lilly and Company
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition